BMS up on ipilimumab in untreated metastatic melanoma
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's novel immunotherapy, ipilimumab, has met the primary endpoint of improving overall survival in previously untreated patients with metastatic melanoma in a Phase III trial, generating a degree of excitement amongst investors.